Panel Discussion: Advancing MRD as a Surrogate Endpoint to Streamline Trial Readouts in Hematology Oncology

Time: 2:00 pm
day: Conference Day 1

Details:

  • Optimizing MRD as a surrogate endpoint in oncology trials
  • Navigating FDA and regulatory expectations around novel endpoints
  • Building successful diagnostic-pharma collaborations to pioneer future trial designs

Speakers: